SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplification

Abstract Background Recent studies have shown an association between certain subunits of the SWI/SNF complex with specific tumor characteristics in gastric cancer (GC). In an earlier study, we applied multiregional whole exome sequencing on multiple primary tumor samples and found alterations of the...

Full description

Bibliographic Details
Main Authors: Katharina Pries, Sandra Krüger, Steffen Heckl, Hans‐Michael Behrens, Christoph Röcken
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.5776
_version_ 1797817663563497472
author Katharina Pries
Sandra Krüger
Steffen Heckl
Hans‐Michael Behrens
Christoph Röcken
author_facet Katharina Pries
Sandra Krüger
Steffen Heckl
Hans‐Michael Behrens
Christoph Röcken
author_sort Katharina Pries
collection DOAJ
description Abstract Background Recent studies have shown an association between certain subunits of the SWI/SNF complex with specific tumor characteristics in gastric cancer (GC). In an earlier study, we applied multiregional whole exome sequencing on multiple primary tumor samples and found alterations of the SWI/SNF complex in 78% of the cases. ERBB2, which encodes for Her2/neu, is a well‐known predictive biomarker used to guide the treatment of GC in the palliative setting. SMARCE1, which encodes for a subunit of the SWI/SNF complex, is localized in close genetic proximity to ERBB2. Aim As little is known about the significance of the SWI/SNF complex in GC biology and the potential relationship between ERBB2 and SMARCE1 upregulation, we examined the expression patterns of SMARCA4 and SMARCE1, two mutually exclusive catalytic ATPase subunits of the SWI/SNF complex, in a well characterized GC cohort. Materials and Methods The expression of SMARCA4 and SMARCE1 was studied by immunohistochemistry in connection with clinicopathological patient characteristics in a cohort of 468 GCs. Digital droplet polymerase chain reaction was performed for amplification analysis on ERBB2 and SMARCE1. Results Immunohistochemical staining of whole‐mount tissue sections found a diffusely “gray scale” expression of SMARCA4 in 446 (95.2%) GCs and of SMARCE1 in 463 (98.8%) GCs. The expression of SMARCA4 and SMARCE1 correlated significantly with ARID1A, p53, and microsatellite status. No correlation was found with the patient prognosis. The amplification analysis of SMARCE1 showed amplification in 4 of 34 cases. In 3 of 34 cases, SMARCE1 was co‐amplified with ERBB2. We also found a co‐expression of SMARCE1 and Her2/neu in a subset of patients. Conclusion While the effect of a co‐amplification is currently unknown, synergistic effects of SMARCE1 and Her2/neu overexpression should be explored in future studies, holding potential for an improved treatment of GC.
first_indexed 2024-03-13T08:56:48Z
format Article
id doaj.art-d2f81867a81d487094ee3ba5a7b83a0f
institution Directory Open Access Journal
issn 2045-7634
language English
last_indexed 2024-03-13T08:56:48Z
publishDate 2023-05-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj.art-d2f81867a81d487094ee3ba5a7b83a0f2023-05-28T20:33:59ZengWileyCancer Medicine2045-76342023-05-01129104231043710.1002/cam4.5776SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplificationKatharina Pries0Sandra Krüger1Steffen Heckl2Hans‐Michael Behrens3Christoph Röcken4Department of Pathology Christian‐Albrechts‐University, University‐Hospital Schleswig‐Holstein Kiel GermanyDepartment of Pathology Christian‐Albrechts‐University, University‐Hospital Schleswig‐Holstein Kiel GermanyDepartment of Internal Medicine II Christian‐Albrechts‐University, University‐Hospital Schleswig‐Holstein Kiel GermanyDepartment of Pathology Christian‐Albrechts‐University, University‐Hospital Schleswig‐Holstein Kiel GermanyDepartment of Pathology Christian‐Albrechts‐University, University‐Hospital Schleswig‐Holstein Kiel GermanyAbstract Background Recent studies have shown an association between certain subunits of the SWI/SNF complex with specific tumor characteristics in gastric cancer (GC). In an earlier study, we applied multiregional whole exome sequencing on multiple primary tumor samples and found alterations of the SWI/SNF complex in 78% of the cases. ERBB2, which encodes for Her2/neu, is a well‐known predictive biomarker used to guide the treatment of GC in the palliative setting. SMARCE1, which encodes for a subunit of the SWI/SNF complex, is localized in close genetic proximity to ERBB2. Aim As little is known about the significance of the SWI/SNF complex in GC biology and the potential relationship between ERBB2 and SMARCE1 upregulation, we examined the expression patterns of SMARCA4 and SMARCE1, two mutually exclusive catalytic ATPase subunits of the SWI/SNF complex, in a well characterized GC cohort. Materials and Methods The expression of SMARCA4 and SMARCE1 was studied by immunohistochemistry in connection with clinicopathological patient characteristics in a cohort of 468 GCs. Digital droplet polymerase chain reaction was performed for amplification analysis on ERBB2 and SMARCE1. Results Immunohistochemical staining of whole‐mount tissue sections found a diffusely “gray scale” expression of SMARCA4 in 446 (95.2%) GCs and of SMARCE1 in 463 (98.8%) GCs. The expression of SMARCA4 and SMARCE1 correlated significantly with ARID1A, p53, and microsatellite status. No correlation was found with the patient prognosis. The amplification analysis of SMARCE1 showed amplification in 4 of 34 cases. In 3 of 34 cases, SMARCE1 was co‐amplified with ERBB2. We also found a co‐expression of SMARCE1 and Her2/neu in a subset of patients. Conclusion While the effect of a co‐amplification is currently unknown, synergistic effects of SMARCE1 and Her2/neu overexpression should be explored in future studies, holding potential for an improved treatment of GC.https://doi.org/10.1002/cam4.5776gastric carcinomaheterogeneityimmunohistochemistryMSISMARCA4SMARCE1
spellingShingle Katharina Pries
Sandra Krüger
Steffen Heckl
Hans‐Michael Behrens
Christoph Röcken
SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplification
Cancer Medicine
gastric carcinoma
heterogeneity
immunohistochemistry
MSI
SMARCA4
SMARCE1
title SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplification
title_full SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplification
title_fullStr SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplification
title_full_unstemmed SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplification
title_short SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co‐amplification
title_sort smarca4 and smarce1 in gastric cancer correlation with arid1a and microsatellite stability and smarce1 erbb2 co amplification
topic gastric carcinoma
heterogeneity
immunohistochemistry
MSI
SMARCA4
SMARCE1
url https://doi.org/10.1002/cam4.5776
work_keys_str_mv AT katharinapries smarca4andsmarce1ingastriccancercorrelationwitharid1aandmicrosatellitestabilityandsmarce1erbb2coamplification
AT sandrakruger smarca4andsmarce1ingastriccancercorrelationwitharid1aandmicrosatellitestabilityandsmarce1erbb2coamplification
AT steffenheckl smarca4andsmarce1ingastriccancercorrelationwitharid1aandmicrosatellitestabilityandsmarce1erbb2coamplification
AT hansmichaelbehrens smarca4andsmarce1ingastriccancercorrelationwitharid1aandmicrosatellitestabilityandsmarce1erbb2coamplification
AT christophrocken smarca4andsmarce1ingastriccancercorrelationwitharid1aandmicrosatellitestabilityandsmarce1erbb2coamplification